In clinical trials, PD1 inhibitors have shown remarkable efficacy in patients with advanced cancers of various etiologies including melanoma, renal cell carcinoma, non-small cell lung cancer, and colorectal carcinoma.11,12. The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.